COVID-Compromise

A more severe course of COVID-19 infections has been reported in immunocompromised patients (ICPs), such as those suffering from innate immune disorders, (haematological) malignancies, or patients who are treated with immunosuppressive medication. The common denominator among
these patients is an impaired B-cell or T-cell function, or depletion, and these patients are unable to generate sufficient neutralizing antiviral antibody titres or their production is delayed. To date, no specific therapeutic strategies have convincingly been shown effective in this patient population. Treatment with neutralizing antiviral antibodies from convalescent patients has been tested in the general population. In this population, one study has shown promising results when it is administered in the very first stages of disease, but not in hospitalized patients. This discrepancy is thought to result from the redundant effect of exogenous antibodies in these patients, in whom high titres of neutralizing antibodies are typically present at hospital admission. In those who are still antibody negative at admission, all but few start producing antibodies within days after admission as well. Since immunocompromised patients may not develop neutralizing antibodies, exogenously provided antibodies could be a functional adjuvant therapy of COVID-19, also in later stages of disease (e.g. upon hospitalization), but no trials to data have addressed this question.

To generate proof that convalescent antibody-mediated treatment of ICPs, who suffer from COVID-19
disease can protect ICPs from a more severe course of disease.

clinical until 28 days.

treatment with Nanogam (purified immunoglobulin concentrate) with or without high dose neutralizing anti COVID-19 antibodies